Correlation of Expression Levels of Copper Transporter 1 and Thymidylate Synthase with Treatment Outcomes in Patients with Advanced Non-small Cell Lung Cancer Treated with S-1/Carboplatin Doublet Chemotherapy

• Published in: Asian Pacific journal of cancer prevention : APJCP Vol. 19; no. 2; pp. 435 - 441
• Main Authors: Konishi, Maho, Imai, Asuka, Fujii, Masanori, Sugimoto, Keisuke, Katakami, Nobuyuki, Imai, Yukihiro, Kamoshida, Shingo
• Format: Journal Article
• Language: English
• Published: Thailand West Asia Organization for Cancer Prevention 26.02.2018
• Subjects: Adenocarcinoma - drug therapy; Adenocarcinoma - metabolism; Adenocarcinoma - mortality; Adenocarcinoma - pathology; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biomarkers, Tumor; Carboplatin - administration & dosage; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - metabolism; Carcinoma, Non-Small-Cell Lung - mortality; Carcinoma, Non-Small-Cell Lung - pathology; Cation Transport Proteins - metabolism; Copper Transporter 1; Drug Combinations; Female; Follow-Up Studies; Humans; Lung Neoplasms - drug therapy; Lung Neoplasms - metabolism; Lung Neoplasms - mortality; Lung Neoplasms - pathology; Male; Middle Aged; Neoplasm Staging; Oxonic Acid - administration & dosage; Survival Rate; Tegafur - administration & dosage; Thymidylate Synthase - metabolism; Treatment Outcome; non-small cell lung cancer; thymidylate synthase; Copper transporter 1; S-1; carboplatin

Background: Copper transporter 1 (CTR1) is a critical determinant of the uptake and cytotoxic effect of the platinum drugs carboplatin and cisplatin. Thymidylate synthase (TS) is an enzyme involved in DNA synthesis and is associated with resistance of tumor cells to 5-fluorouracil. We investigated t...